首页|Oral peptide therapeutics for diabetes treatment:State-of-the-art and future perspectives
Oral peptide therapeutics for diabetes treatment:State-of-the-art and future perspectives
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NETL
NSTL
万方数据
Diabetes,characterized by hyperglycemia,is a major cause of death and disability world-wide.Peptides,such as insulin and glucagon-like peptide-1(GLP-1)analogs,have shown promise as treatments for diabetes due to their ability to mimic or enhance insulin's actions in the body.Compared to subcutaneous injection,oral administration of anti-diabetic peptides is a preferred approach.However,biological barriers significantly reduce the efficacy of oral peptide therapeutics.Recent advancements in drug delivery systems and formulation techniques have greatly improved the oral delivery of peptide ther-apeutics and their efficacy in treating diabetes.This review will highlight(1)the benefits of oral anti-diabetic peptide therapeutics;(2)the biological barriers for oral peptide delivery,including pH and enzyme degradation,intestinal mucosa barrier,and biodistribution barrier;(3)the delivery platforms to overcome these biological barriers.Additionally,the review will discuss the prospects in this field.The information provided in this review will serve as a valuable guide for future developments in oral anti-diabetic peptide therapeutics.
State Key Laboratory of Drug Research and Center of Pharmaceutics,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China
University of Chinese Academy of Sciences,Beijing 100049,China
School of Pharmacy,Henan University,Kaifeng 475004,China
NMPA Key Laboratory for Quality Research and Evaluation of Pharmaceutical Excipients,National Institutes for Food and Drug Control,Beijing 100050,China
展开 >
National Science Fund of Distinguished Young Scholars,China国家自然科学基金Key Research Program of Chinese Academy of sciences,ChinaYoung Elite Scientists Sponsorship Program by CAST,China
NETL
NSTL
万方数据
